Matthew Ronsheim - 16 Jul 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc.

Role
Chief of Pharmaceutical Sciences and Manufacturing
Signature
Elizabeth M. Keiley as attorney-in-fact for Matthew Ronsheim
Issuer symbol
N/A
Transactions as of
16 Jul 2021
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 15:04:44 UTC
Next filing
20 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -40,000 -100% 0 16 Jul 2021 Common Stock 40,000 $5.12 Direct F1, F2
transaction ETTX Employee Stock Option (Right to Buy) Award +33,333 33,333 16 Jul 2021 Common Stock 33,333 $2.44 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on September 17, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share.
F3 Sixty-nine percent (69%) of this award will vest on July 16, 2022, and one-fifteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.

Remarks:

Chief of Pharmaceutical Sciences and Manufacturing